ArticleTheranostics2020
Development of a new class of PSMA radioligands comprising ibuprofen as an albumin-binding entity.
Article in Theranostics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 92 citations in OpenAlex.
- Albumin-Binding Moieties Tune the Pharmacokinetics and Tumor Uptake ofACS medicinal chemistry letters · 2026Article
- Tolerability of [European journal of nuclear medicine and molecular imaging · 2026Article
- Preclinical evaluation ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Effect of a Negatively Charged Amino Acid Linker on the Tumor-Targeting Properties of [ACS pharmacology & translational science · 2026Article
- Safety and efficacy of [European journal of nuclear medicine and molecular imaging · 2026Article
- Phase I dose-escalation study of [¹⁷⁷Lu]Lu-LNC1011, a long-circulating dansyl-modified PSMA theranostics, in metastatic castration-resistant prostate cancer.Theranostics · 2026Article
- Evaluation of folate receptor-alpha and other surface markers as potential targets for radionuclide therapy of ovarian cancer.EJNMMI research · 2025Article
- Rate-Tunable, Metal-Mediated Amide Bond Cleavage for the Controlled Release of Pharmaceuticals.Journal of the American Chemical Society · 2025Article
- Tailored Reaction Conditions and Automated Radiolabeling of [International journal of molecular sciences · 2025Article
- Enhancing the Half-Life of ODAP-Urea Based Radioligands by Incorporating Albumin-Binding Moieties.Molecular imaging and biology · 2025Article
- Design and characterization of a novel prostate-specific membrane antigen-targeted radioligand modified with a fatty acid albumin binder for optimized circulation half-life.EJNMMI radiopharmacy and chemistry · 2025Article
- Biodistribution-Driven Discovery Identifies a Glycosidase-Cleavable Linker to Reprogram Radiotheranostics.bioRxiv : the preprint server for biology · 2025Article
- Biodistribution and dosimetry of [European journal of nuclear medicine and molecular imaging · 2025Article
- Comparison of carbonic anhydrase-IX-targeted trifunctional radioligands between linear- and branched-chain arrangements.Frontiers in nuclear medicine · 2025Article
- Effect of Ibuprofen as an Albumin Binder on Melanoma-Targeting Properties ofMolecular pharmaceutics · 2024Article
- New tactics in the design of theranostic radiotracers.Npj imaging · 2024Review
- Optimizing the pharmacokinetics of anEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going.Cancer treatment reviews · 2024Review
- Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled withACS pharmacology & translational science · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen (PSMA)-targeted radioligands have been used for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Recently, albumin-binding PSMA radioligands with enhanced blood circulation were developed to increase the tumor accumulation of activity. The present study aimed at the design, synthesis and preclinical evaluation of a novel class of PSMA-targeting radioligands equipped with ibuprofen as a weak albumin-binding entity in order to improve the pharmacokinetic properties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.